Morgan Stanley grew its position in Omnicell, Inc. (NASDAQ:OMCL) by 21.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,915 shares of the company’s stock after buying an additional 52,106 shares during the period. Morgan Stanley owned 0.70% of Omnicell worth $19,536,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Omnicell in the 4th quarter worth approximately $30,171,000. Bank of New York Mellon Corp grew its position in Omnicell by 62.3% during the 1st quarter. Bank of New York Mellon Corp now owns 877,992 shares of the company’s stock worth $57,578,000 after purchasing an additional 337,035 shares during the last quarter. Ziegler Capital Management LLC purchased a new position in Omnicell during the 1st quarter worth $10,100,000. Marshall Wace LLP grew its position in Omnicell by 1,894.2% during the 4th quarter. Marshall Wace LLP now owns 142,788 shares of the company’s stock worth $11,668,000 after purchasing an additional 135,628 shares during the last quarter. Finally, Credit Suisse AG grew its position in Omnicell by 7.3% during the 4th quarter. Credit Suisse AG now owns 1,470,180 shares of the company’s stock worth $120,143,000 after purchasing an additional 99,580 shares during the last quarter. 95.89% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently weighed in on the stock. BidaskClub raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Piper Sandler lowered their target price on shares of Omnicell from $88.00 to $76.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Benchmark lowered their target price on shares of Omnicell from $96.00 to $82.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Cantor Fitzgerald lowered their target price on shares of Omnicell from $95.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, ValuEngine downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Friday, April 17th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $84.25.
Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, May 7th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.15. Omnicell had a net margin of 7.51% and a return on equity of 11.37%. The firm had revenue of $229.69 million during the quarter, compared to the consensus estimate of $218.99 million. During the same period in the previous year, the firm earned $0.61 earnings per share. Omnicell’s revenue was up 13.4% compared to the same quarter last year. Equities analysts expect that Omnicell, Inc. will post 1.8 earnings per share for the current year.
In other news, EVP Scott Peter Seidelmann sold 2,125 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $67.70, for a total transaction of $143,862.50. Following the transaction, the executive vice president now directly owns 33,385 shares of the company’s stock, valued at $2,260,164.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Randall A. Lipps sold 5,000 shares of the business’s stock in a transaction on Friday, April 3rd. The stock was sold at an average price of $66.11, for a total transaction of $330,550.00. Following the transaction, the chief executive officer now directly owns 159,266 shares in the company, valued at $10,529,075.26. The disclosure for this sale can be found here. 2.63% of the stock is owned by insiders.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Read More: Inverted Yield Curve
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.